Skip to content
ClosedUnited KingdomGoods£15,169,777

Transitional Drugs 3

Published
Published 19 December 2024
Deadline
Closed 23 January 2025

Overview

Drugs which have recently lost their patent exclusivity

Key details

Country
United Kingdom
Status
Closed
Category
Goods
Estimated value
£15,169,777
Procedure
Open
Published
19 December 2024
Deadline
Closed
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
£29,045,630
Award date
14 April 2025
Contract period
31 March 2025 → 30 June 2026
Winners
  • Amgen Ltd
  • Biogen Idec Ltd
  • Celix Pharma
  • Celltrion Healthcare Uk Ltd
  • Fresenius Kabi Ltd
  • Roche Products Ltd
  • Sandoz Ltd
  • Sun Pharma Ltd
  • Thornton & Ross Ltd
  • Tillomed Laboratories Ltd
  • Zentiva Ltd

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract

    14 May 2025

    View notice ↗
  2. Contract Notice

    19 December 2024

    View notice ↗

Contracting authority

  • Velindre NHS Trust

    Buyer

    Newport, United Kingdom

    Authority website ↗
  • Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales UHBs & Trusts

    Buyer

    Newport, United Kingdom

    Authority website ↗

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Transitional Drugs 3 — won by Amgen Ltd +10 — Skim